Managing SSc-ILD: Mapping the Disease Course

• Overview: disease progression in autoimmune ILD
• Methods of monitoring disease progression
• Monitoring SSc-ILD, a heterogeneous disease
• Identifying opportunities for early intervention

Chronic Fibrosing Interstitial Lung Disease with a Progressive Phenotype: A Multidisciplinary Roundtable Discussion

Insights in ILD: Management of chronic fibrosing ILDs with a progressive phenotype

• Progressive Fibrosis in Interstitial Lung Disease
• Pulmonary Rehabilitation in ILD
• Palliative Care for ILD
• Managing Refractory Breathlessness in Fibrotic ILDs

Insights in ILD: The Microbiome and ILD

• The role of the microbiome in the pathogenesis of interstitial lung diseases
• Lung microbiome may predict IPF progression
• Sarcoidosis is not impacted by microbiota

Classifying ILDs: Genetic and Molecular Trends

• The influence of nomenclature upon research and clinical care
• Genetic markers of interstitial lung disease
• Molecular endophenotypes of interstitial lung disease
• Etiology details that drive clinical decision making

High-Resolution CT in Interstitial Lung Diseases

• What are the high-resolution computed tomography (HRCT)features of a fibrotic lung?
• What general HRCT features distinguish among HP, autoimmune ILD,and sarcoidosis?
• How do HRCT features evolve with disease progression?
• What is the potential for machine learning to automatically detect HRCT features of lung disease?
• MRI vs CT scan of the lungs: advantages and pitfalls

What Is the Pathogenesis of CTDs and CTD‑ILDs?

• How Do We Identify CTD Overlap Syndromes and What Does This Mean for Treatment of CTD‑ILD?
• How Can Serologies in Suspected CTD Point to ILD Disease Severity?
• Pulmonary Arterial Hypertension (PAH) and ILD Are not Mutually Exclusive in Systemic Sclerosis (SSc)

Evaluation, Diagnosis, and Management of Systemic Sclerosis—Associated Interstitial Lung Disease: A Multidisciplinary Roundtable Discussion